TITLE

What is the best evidence for determining harms of medical treatment?

AUTHOR(S)
Vandenbroucke, Jan P.
PUB. DATE
February 2006
SOURCE
CMAJ: Canadian Medical Association Journal;2/28/2006, Vol. 174 Issue 5, p645
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article examines a study that compared evidence on adverse effects from medical interventions reported in randomized and nonrandomized studies. Data from observational studies on adverse effects must be considered aside from data from randomized controlled trials. Most of the adverse effects reported by the authors were said to be pharmacologically predictable.
ACCESSION #
20256879

 

Related Articles

  • Low quality of reporting adverse drug reactions in paediatric randomised controlled trials. de Vries, Tjalling W.; van Roon, Eric N. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Dec2010, Vol. 95 Issue 12, p1023 

    Objective Randomised controlled trials (RCT) offer an opportunity to learn about frequency and character of adverse drug reactions. To improve the quality of reporting adverse effects, the Consort group published recommendations. The authors studied the application of these recommendations in...

  • Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials. Rief, Winfried; Nestoriuc, Yvonne; von Lilienfeld-Toal, Anna; Dogan, Imis; Schreiber, Franziska; Hofmann, Stefan G.; Barsky, Arthur I.; Avorn, Jerry // Drug Safety;2009, Vol. 32 Issue 11, p1041 

    Background: Biases in adverse effect reporting in randomized controlled trials (RCTs) [e.g. due to investigator expectations or assessment quality] can be quantified by studying the rates of adverse events reported in the placebo arms of such trials. Objective: We compared the rates of adverse...

  • Net Efficacy Adjusted for Risk (NEAR): A Simple Procedure for Measuring Risk:Benefit Balance. Boada, José N.; Boada, Carlos; García-Sáiz, Mar; García, Marcelino; Fernández, Eduardo; Gómez, Eugenio // PLoS ONE;2008, Vol. 3 Issue 10, p1 

    Background: Although several mathematical models have been proposed to assess the risk:benefit of drugs in one measure, their use in practice has been rather limited. Our objective was to design a simple, easily applicable model. In this respect, measuring the proportion of patients who respond...

  • Sustained-Release Bupropion for Smoking Cessation in a Chinese Sample: A Double-Blind, Placebo-Controlled, Randomized Trial. Sheng, Li-xia; Tang, Yi-lang; Jiang, Zuo-ning; Yao, Chong-hua; Gao, Jun-yu; Xu, Guo-Zhu; Tong, Xin-yuan // Nicotine & Tobacco Research;Feb2013, Vol. 15 Issue 2, p320 

    Introduction: Bupropion is a first-line pharmacological aid for smoking cessation; however, no clinical trials have been conducted in a Chinese population. Methods: We enrolled 248 smokers in a hospital-based, randomized, smoking cessation trial conducted at four outpatient centers in Beijing. A...

  • Abstracts in high profile journals often fail to report harm. Bernal-Delgado, Enrique; Fisher, Elliot S. // BMC Medical Research Methodology;2008, Vol. 8, Special section p1 

    Background: To describe how frequently harm is reported in the abstract of high impact factor medical journals. Methods: Design and population: We carried out a blinded structured review of a random sample of 363 Randomised Controlled Trials (RCTs) carried out on human beings, and published in...

  • Long-term treatment of depression with antidepressants: a systematic narrative review. Furukawa, Toshi A.; Cipriani, Andrea; Barbui, Corrado; Geddes, John R. // Canadian Journal of Psychiatry;Sep2007, Vol. 52 Issue 9, p545 

    Objective: To examine the available scientific evidence for answers to clinically relevant questions on the effectiveness and tolerability of antidepressant drugs (ADs) for the long-term treatment of depression.Method: The Cochrane Library was searched up to July 2006....

  • Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age. Desta, Z; Kreutz, Y; Nguyen, A T; Li, L; Skaar, T; Kamdem, L K; Henry, N L; Hayes, D F; Storniolo, A M; Stearns, V; Hoffmann, E; Tyndale, R F; Flockhart, D A // Clinical Pharmacology & Therapeutics;Nov2011, Vol. 90 Issue 5, p693 

    The associations between plasma letrozole concentrations and CYP2A6 and CYP3A5 genetic variants were tested in the Exemestane and Letrozole Pharmacogenomics (ELPH) trial. ELPH is a multicenter, open-label prospective clinical trial in women randomly assigned (n ≈ 250 in each arm) to...

  • Efficacy and safety of a levonorgestrel enteric-coated tablet as an over-the-counter drug for emergency contraception: a Phase IV clinical trial. Chen, Q.-J.; Xiang, W.-P.; Zhang, D.-K.; Wang, R.-P.; Luo, Y.-F.; Kang, J.-Z.; Cheng, L.-N. // Human Reproduction;Sep2011, Vol. 26 Issue 9, p2316 

    BACKGROUND An enteric-coated levonorgestrel emergency contraceptive pill (E-LNG-ECP) is an improved formulation, in terms of side effects, which both dissolves and is absorbed in the intestine. Our aim was to evaluate the efficacy and safety of E-LNG-ECP as an over-the-counter (OTC) drug for...

  • Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types. McKeage, Mark J. // Drugs;2007, Vol. 67 Issue 6, p859 

    Satraplatin is the first orally administered platinum drug to be evaluated in the clinic. Oral satraplatin plus prednisone improved progression free survival significantly relative to prednisone alone in patients with hormone-refractory prostate cancer in a randomised study. Furthermore,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics